Lexaria Bioscience (LXRP) News Today Add Compare Share Share Headlines Stock Analysis All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Lexaria Bioscience Corp.: Lexaria's Strategic Business Pursuit of DehydraTECH-LiraglutideFebruary 20 at 8:18 AM | finanznachrichten.deLexaria Bioscience stock hits 52-week low at $1.62February 11, 2025 | msn.comLexaria reports promising drug delivery study resultsJanuary 30, 2025 | msn.comLexaria CEO says FY25 R&D will ‘remain concentrated’ on GLP-1 investigationsJanuary 30, 2025 | markets.businessinsider.comLexaria Bioscience Strengthens GLP-1 Drug Delivery Focus and Expands Patent Portfolio in 2024January 30, 2025 | tipranks.comLexaria Bioscience price target lowered to $7 from $10 at H.C. WainwrightJanuary 24, 2025 | markets.businessinsider.comLexaria’s Human GLP-1 Study #5 Receives Independent Review Board ApprovalJanuary 17, 2025 | finance.yahoo.comLexaria’s human GLP-1 study 5 receives IRB approvalJanuary 17, 2025 | markets.businessinsider.comLexaria Bioscience Corp.: Lexaria's Human GLP-1 Study #5 Receives Independent Review Board ApprovalJanuary 15, 2025 | finanznachrichten.deLexaria Bioscience Advances with Human Study for Oral LiraglutideJanuary 15, 2025 | tipranks.comLexaria Bioscience announces partial results from GLP-1-H24-3 studyJanuary 15, 2025 | markets.businessinsider.comH.C. Wainwright maintains Buy rating on Lexaria Bioscience stockDecember 26, 2024 | uk.investing.comLexaria Bioscience Corp.: Esteemed Harvard Medical School Professor Dr. Michael Gibson Appointed Chief Medical Advisor at Lexaria BioscienceDecember 20, 2024 | finanznachrichten.deLexaria Bioscience’s Oral Tirzepatide Study ProgressesNovember 26, 2024 | markets.businessinsider.comPositive Partial 12-Week Body Weight Results from Lexaria’s GLP-1 Diabetes Animal StudyOctober 22, 2024 | finance.yahoo.comLexaria Updates Current GLP-1 MarketOctober 8, 2024 | finance.yahoo.comLexaria (NASDAQ: LEXX) Evaluating ‘More Effective, Tolerable’ Oral Delivery of GLP-1 DrugsSeptember 25, 2024 | theglobeandmail.comLexaria (NASDAQ: LEXX) Hires New CEO Amid Shift in Focus to Pharmaceutical CollaborationSeptember 24, 2024 | theglobeandmail.comLexaria (NASDAQ: LEXX) Eyeing Market Potential with Unique Delivery Platform, GLP-1 ProgramSeptember 17, 2024 | theglobeandmail.comLexaria Bioscience Corp.: Lexaria's Second GLP-1 Human Pilot Study Shows Zero Adverse Events in DehydraTECH-processed Rybelsus Oral CapsulesAugust 29, 2024 | finanznachrichten.deLexaria Bioscience Corp.: Positive 8-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal StudyAugust 25, 2024 | finanznachrichten.deTinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyeing Opportunity from First-Ever Work with Tirzepatide MoleculeAugust 16, 2024 | msn.comLexaria Bioscience (NASDAQ: LEXX) Exploring Alternative Diabetes and Obesity TreatmentsAugust 9, 2024 | theglobeandmail.comLEXX Stock Earnings: Lexaria Bioscience Misses EPS, Misses Revenue for Q3 2024July 12, 2024 | investorplace.comLexaria Bioscience (NASDAQ: LEXX) Selects CRO in Third GLP-1 Human Pilot StudyMay 24, 2024 | theglobeandmail.comLexaria Awards Contract For Third GLP-1 Human Pilot StudyMay 23, 2024 | finance.yahoo.comLexaria begins study on enhanced drug delivery technologyMay 19, 2024 | investing.comDosing Begins in Lexaria's Comprehensive GLP-1 Animal StudyMay 17, 2024 | finance.yahoo.comHere's Why We're Watching Lexaria Bioscience's (NASDAQ:LEXX) Cash Burn SituationMay 9, 2024 | finance.yahoo.comLexaria gets ethics board okay for oral GLP-1 studyApril 16, 2024 | msn.comLexaria (NASDAQ: LEXX) Hires Research Organization to Perform GLP-1 Human Pilot StudyMarch 27, 2024 | theglobeandmail.comLexaria appoints Nelson Cabatuan as CFOMarch 14, 2024 | msn.comLexaria Bioscience (NASDAQ: LEXX) Banking on DehydraTECH(TM) for Major 2024 GrowthMarch 11, 2024 | theglobeandmail.comLexaria Bioscience Corp.: Lexaria Announces Closing of $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesFebruary 16, 2024 | finanznachrichten.deWhy Lexaria Bioscience (LEXX) Shares Are MovingFebruary 15, 2024 | msn.comLexaria Unveils Extensive Planned 2024 GLP-1 Study ProgramJanuary 16, 2024 | finance.yahoo.comLexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Drug-Delivery System Improves Way Molecules Enter BloodstreamJanuary 11, 2024 | finance.yahoo.comLEXX: GLP-1s’ Sweet OpportunityNovember 30, 2023 | msn.comLexaria Bioscience Corp. (NASDAQ: LEXX) Expands Studies of Proprietary Platform in Multibillion-Dollar GLP-1 Drug SpaceNovember 1, 2023 | finance.yahoo.comLexaria Bioscience’s Growth Prospects: New Licensing Agreement, Advanced Core Pipeline, and Positive Clinical TrialsOctober 18, 2023 | markets.businessinsider.comLexaria Enters New Global Exclusive Collaboration and License Agreement with SulfoSynOctober 13, 2023 | finance.yahoo.comLexaria Bioscience (NASDAQ: LEXX) Expands Portfolio in Oral Nicotine Delivery SectorAugust 5, 2023 | msn.comLexaria Bioscience Corp.: Lexaria's Plans to Study Weight Loss and Diabetes Control in a Human Clinical Study with DehydraTECH-CBDAugust 2, 2023 | finanznachrichten.deLexaria Bioscience (NASDAQ: LEXX, LEXXW) Announces New Subsidiary, Provides Update on Nicotine StudyJuly 29, 2023 | theglobeandmail.comLexaria Bioscience Corp.: Lexaria Incorporates New Subsidiary for CPG Products and Updates Human Nicotine StudyJuly 28, 2023 | finanznachrichten.deLexaria Incorporates New Subsidiary for CPG Products and Updates Human Nicotine StudyJuly 28, 2023 | finance.yahoo.comLexaria Bioscience Corp.: Lexaria Granted Strategically Important New US Patent For DehydraTECH-Nicotine Including Oral Pouch ProductsJuly 19, 2023 | finanznachrichten.deLexaria Bioscience Corp.: Lexaria Announces 2023 Annual Meeting ResultsMay 10, 2023 | finanznachrichten.deLexaria Announces 2023 Annual Meeting ResultsMay 10, 2023 | finance.yahoo.comLexaria Bioscience (NASDAQ: LEXX) Announces Dosing Completed on Human Nicotine StudyMay 9, 2023 | theglobeandmail.com Get Lexaria Bioscience News Delivered to You Automatically Sign up to receive the latest news and ratings for LXRP and its competitors with MarketBeat's FREE daily newsletter. Email Address LXRP Media Mentions By Week LXRP Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LXRP News Sentiment▼0.000.60▲Average Medical News Sentiment LXRP News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LXRP Articles This Week▼10▲LXRP Articles Average Week Get Lexaria Bioscience News Delivered to You Automatically Sign up to receive the latest news and ratings for LXRP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Augusta Gold News Today American Lithium News Today American Lithium News Today Bunker Hill Mining News Today Westwater Resources News Today Augusta Gold News Today Quaterra Resources News Today Pacific Booker Minerals News Today Mountain Province Diamonds News Today Verify Smart News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:LXRP) was last updated on 2/23/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredNvidia > DeepSeekEveryone's getting it all wrong … Sure, DeepSeek's reveal caused AI stocks to tumble … But, in the long ...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexaria Bioscience Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexaria Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
